A Comprehensive Systematic Review of The Effectiveness of Pharmacological Therapies For Osteoporosis in Males
Keywords:
Osteoporosis, fragility, fracture, men, boneAbstract
Background: Studies show that osteoporosis, a condition with low bone mineral density, increases the risk of fragility fractures, leading to higher mortality rates, disability, and increased healthcare expenses. Men are at higher risk, and pharmacological therapies have been found effective in reducing fracture risk, with zoledronate having the most significant effect on increasing lumbar spine bone mineral density. Methods: We conducted a search without sample size restrictions in the PubMed and Web of Science databases to find prospective studies on the effectiveness of pharmacologic therapies in men with osteoporosis. The analysis comprised a total of eight published prospective studies. Result: After a thorough three-step screening process, eight papers were determined to have pertinent connections to our current in-depth investigation. Following that, a close reading of the entire text was conducted, with additional attention being paid to these specific passages. Conclusion: Studies on osteoporosis treatments, such as alendronate, risedronate, zoledronic acid, ibandronate, denosumab, teriparatide abaloparatide, and romosozumab, show effectiveness in improving bone mineral density in men with the condition. However, evidence is limited due to unexplained differences.
References
Compston, J. E., Mcclung, M. R., & Leslie, W. D. (2019). Osteoporosis. 393, 364–376. https://doi.org/10.1016/S0140-6736(18)32112-3
Schuit, S. C. E., Klift, M. Van Der, Weel, A. E. A. M., Laet, C. E. D. H. De, Burger, H., Seeman, E., Hofman, A., Uitterlinden, A. G., Leeuwen, J. P. T. M. Van, & Pols, H. A. P. (2004). Fracture incidence and association with bone mineral density in elderly men and women : the Rotterdam Study. 34, 195–202. https://doi.org/10.1016/j.bone.2003.10.001
Siris, E. S., Chen, Y., Abbott, T. A., Barrett-connor, E., Miller, P. D., Wehren, L. E., & Berger, M. L. (2015). Bone Mineral Density Thresholds for Pharmacological Intervention to Prevent Fractures. 164.
Wells, G. A., Cranney, A., Peterson, J., Boucher, M., Shea, B., Robinson, V., Coyle, D., & Tugwell, P. (2008). Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. The Cochrane database of systematic reviews, (1), CD001155. https://doi.org/10.1002/14651858.CD001155.pub2
Kendler, D. L., Marin, F., Zerbini, C. A. F., Russo, L. A., Greenspan, S. L., Zikan, V., Bagur, A., Malouf-sierra, J., & López-romero, P. (2017). Articles Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis ( VERO ): controlled trial. 6736(17), 1–11. https://doi.org/10.1016/S0140-6736(17)32137-2
Saag, K. G., Petersen, J., Brandi, M. L., Thomas, T., Ph, D., Maddox, J., Fan, M., Ph, D., Meisner, P. D., Pharm, D., & Grauer, A. (2017). Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. 1–11. https://doi.org/10.1056/NEJMoa1708322
Händel, M. N., Cardoso, I., von Bülow, C., Rohde, J. F., Ussing, A., Nielsen, S. M., Christensen, R., Body, J.-J., Brandi, M. L., Diez-Perez, A., Hadji, P., Javaid, M. K., Lems, W. F., Nogues, X., Roux, C., Minisola, S., Kurth, A., Thomas, T., Prieto-Alhambra, D., … Abrahamsen, B. (2023). Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials. BMJ (Clinical Research Ed.), 381, e068033. https://doi.org/10.1136/bmj-2021-068033
Kanis, J.A. (2007) Assessment of Osteoporosis at the Primary Health Care Level. Technical Report, World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield.
Vandenput, L., Johansson, H., McCloskey, E. V, Liu, E., Åkesson, K. E., Anderson, F. A., Azagra, R., Bager, C. L., Beaudart, C., Bischoff-Ferrari, H. A., Biver, E., Bruyère, O., Cauley, J. A., Center, J. R., Chapurlat, R., Christiansen, C., Cooper, C., Crandall, C. J., Cummings, S. R., … Kanis, J. A. (2022). Update of the fracture risk prediction tool FRAX: a systematic review of potential cohorts and analysis plan. Osteoporosis International : A Journal Established as Result of Cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 33(10), 2103–2136. https://doi.org/10.1007/s00198-022-06435-6
Kanis, J. A., Johnell, O., Oden, A., Johansson, H., & McCloskey, E. (2008). FRAX and the assessment of fracture probability in men and women from the UK. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 19(4), 385–397. https://doi.org/10.1007/s00198-007-0543-5
Kanis, J. A., Harvey, N. C., Johansson, H., Liu, E., Vandenput, L., Lorentzon, M., Leslie, W. D., & McCloskey, E. V. (2020). A decade of FRAX: how has it changed the management of osteoporosis?. Aging clinical and experimental research, 32(2), 187–196. https://doi.org/10.1007/s40520-019-01432-y
Eastell, R., Vittinghoff, E., Lui, L. Y., McCulloch, C. E., Pavo, I., Chines, A., Khosla, S., Cauley, J. A., Mitlak, B., Bauer, D. C., Bouxsein, M., & Black, D. M. (2022). Validation of the Surrogate Threshold Effect for Change in Bone Mineral Density as a Surrogate Endpoint for Fracture Outcomes: The FNIH-ASBMR SABRE Project. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 37(1), 29–35. https://doi.org/10.1002/jbmr.4433
Beaudart, C., Demonceau, C., Sabico, S., Veronese, N., Cooper, C., Harvey, N., Fuggle, N., Bruyère, O., Rizzoli, R., & Reginster, J. Y. (2023). Efficacy of osteoporosis pharmacological treatments in men: a systematic review and meta-analysis. Aging clinical and experimental research, 35(9), 1789–1806. https://doi.org/10.1007/s40520-023-02478-9
Chen, L. X., Zhou, Z. R., Li, Y. L., Ning, G. Z., Zhang, T. S., Zhang, D., & Feng, S. Q. (2015). Comparison of Bone Mineral Density in Lumbar Spine and Fracture Rate among Eight Drugs in Treatments of Osteoporosis in Men: A Network Meta-Analysis. PloS one, 10(5), e0128032. https://doi.org/10.1371/journal.pone.0128032
Nayak, S., & Greenspan, S. L. (2017). Osteoporosis Treatment Efficacy for Men: A Systematic Review and Meta-Analysis. Journal of the American Geriatrics Society, 65(3), 490–495. https://doi.org/10.1111/jgs.14668
Czerwinski, E., Cardona, J., Plebanski, R., Recknor, C., Vokes, T., Saag, K. G., Binkley, N., Lewiecki, E. M., Adachi, J., Knychas, D., Kendler, D., Orwoll, E., Chen, Y., Pearman, L., Li, Y. H., & Mitlak, B. (2022). The Efficacy and Safety of Abaloparatide-SC in Men With Osteoporosis: A Randomized Clinical Trial. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 37(12), 2435–2442. https://doi.org/10.1002/jbmr.4719
Matsumoto, T., Sone, T., Soen, S., Tanaka, S., Yamashita, A., & Inoue, T. (2022). Abaloparatide Increases Lumbar Spine and Hip BMD in Japanese Patients With Osteoporosis: The Phase 3 ACTIVE-J Study. The Journal of clinical endocrinology and metabolism, 107(10), e4222–e4231. https://doi.org/10.1210/clinem/dgac486
Qi Y, Wang W, Sun W et al. (2021) Comparative efficacy and safety of alendronate and teriparatide in bone loss reduction and prevention of vertebral fracture in osteoporotic Chinese patients. Trop J Pharm Res 20:2199–2204. https://doi.org/10.4314/tjpr. v20i10.26
Lewiecki, E. M., Blicharski, T., Goemaere, S., Lippuner, K., Meisner, P. D., Miller, P. D., Miyauchi, A., Maddox, J., Chen, L., & Horlait, S. (2018). A Phase III Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men With Osteoporosis. The Journal of clinical endocrinology and metabolism, 103(9), 3183–3193. https://doi.org/10.1210/jc.2017-02163
Nakamura, T., Matsumoto, T., Sugimoto, T., Hosoi, T., Miki, T., Gorai, I., Yoshikawa, H., Tanaka, Y., Tanaka, S., Sone, T., Nakano, T., Ito, M., Matsui, S., Yoneda, T., Takami, H., Watanabe, K., Osakabe, T., Shiraki, M., & Fukunaga, M. (2014). Clinical Trials Express: fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: denosumab fracture intervention randomized placebo controlled trial (DIRECT). The Journal of clinical endocrinology and metabolism, 99(7), 2599–2607. https://doi.org/10.1210/jc.2013-4175
Walker, M. D., Cusano, N. E., Sliney, J., Jr, Romano, M., Zhang, C., McMahon, D. J., & Bilezikian, J. P. (2013). Combination therapy with risedronate and teriparatide in male osteoporosis. Endocrine, 44(1), 237–246. https://doi.org/10.1007/s12020-012-9819-4
Boonen, S., Reginster, J. Y., Kaufman, J. M., Lippuner, K., Zanchetta, J., Langdahl, B., Rizzoli, R., Lipschitz, S., Dimai, H. P., Witvrouw, R., Eriksen, E., Brixen, K., Russo, L., Claessens, F., Papanastasiou, P., Antunez, O., Su, G., Bucci-Rechtweg, C., Hruska, J., Incera, E., … Orwoll, E. (2012). Fracture risk and zoledronic acid therapy in men with osteoporosis. The New England journal of medicine, 367(18), 1714–1723. https://doi.org/10.1056/NEJMoa1204061
Orwoll, E., Teglbjærg, C. S., Langdahl, B. L., Chapurlat, R., Czerwinski, E., Kendler, D. L., Reginster, J. Y., Kivitz, A., Lewiecki, E. M., Miller, P. D., Bolognese, M. A., McClung, M. R., Bone, H. G., Ljunggren, Ö., Abrahamsen, B., Gruntmanis, U., Yang, Y. C., Wagman, R. B., Siddhanti, S., Grauer, A., … Boonen, S. (2012). A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. The Journal of clinical endocrinology and metabolism, 97(9), 3161–3169. https://doi.org/10.1210/jc.2012-1569
US Food and Drug Administration. FDA Public Workshop. Osteoporosis Drug Development: Moving Forward. In: https://www.fda. gov/downloads/drugs/newsevents/ucm470574.pdf
European Medicines Agency. Guideline on the evaluation of medicinal products in the treatment of primary osteoporosis. In: http://www.ema.europa.eu/docs/en_GB/document_library/Scien tific_guideline/2009/09/WC500003405.pdf .
Kanis, J. A., Cooper, C., Rizzoli, R., Reginster, J. Y., & Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF) (2019). Executive summary of the European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Calcified tissue international, 104(3), 235–238. https://doi.org/10.1007/s00223-018-00512-x
Kanis, J. A., McCloskey, E. V., Harvey, N. C., Cooper, C., Rizzoli, R., Dawson-Hughes, B., Maggi, S., & Reginster, J. Y. (2022). Intervention thresholds and diagnostic thresholds in the management of osteoporosis. Aging clinical and experimental research, 34(12), 3155–3157. https://doi.org/10.1007/s40520-022-02216-7
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Putri Ayu, Khoirunnisa (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
